As of 2026-09-15, the Relative Valuation of Intellia Therapeutics Inc (NTLA) is (79.15) USD. This relative valuation is based on P/E multiples. With the latest stock price at 11.87 USD, the upside of Intellia Therapeutics Inc based on Relative Valuation is -766.8%.
The range of the Relative Valuation is (74.26) - (86.22) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 22.7x - 30.1x | 26.8x |
| Forward P/E multiples | 25.9x - 32.9x | 28.6x |
| Fair Price | (74.26) - (86.22) | (79.15) |
| Upside | -725.6% - -826.4% | -766.8% |
| Date | P/E |
| 2026-09-15 | -3.99 |
| 2026-09-14 | -4.15 |
| 2026-09-11 | -4.10 |
| 2026-09-10 | -4.17 |
| 2026-09-09 | -4.27 |
| 2026-09-08 | -4.45 |
| 2026-09-04 | -4.45 |
| 2026-09-03 | -4.43 |
| 2026-09-02 | -4.46 |
| 2026-09-01 | -4.43 |
| 2026-08-31 | -4.45 |
| 2026-08-28 | -4.50 |
| 2026-08-27 | -4.58 |
| 2026-08-26 | -4.61 |
| 2026-08-25 | -4.72 |
| 2026-08-24 | -4.39 |
| 2026-08-21 | -4.49 |
| 2026-08-20 | -4.35 |
| 2026-08-19 | -4.64 |
| 2026-08-18 | -4.05 |
| 2026-08-17 | -4.22 |
| 2026-08-14 | -4.16 |
| 2026-08-13 | -4.13 |
| 2026-08-12 | -4.22 |
| 2026-08-11 | -4.20 |
| 2026-08-10 | -4.20 |
| 2026-08-07 | -4.17 |
| 2026-08-06 | -3.93 |
| 2026-08-05 | -3.83 |
| 2026-08-04 | -3.95 |
| 2026-08-03 | -3.76 |
| 2026-07-31 | -3.73 |
| 2026-07-30 | -3.87 |
| 2026-07-29 | -3.77 |
| 2026-07-28 | -3.80 |
| 2026-07-27 | -3.73 |
| 2026-07-24 | -3.75 |
| 2026-07-23 | -3.88 |
| 2026-07-22 | -3.89 |
| 2026-07-21 | -4.01 |
| 2026-07-20 | -3.81 |
| 2026-07-17 | -3.97 |
| 2026-07-16 | -4.14 |
| 2026-07-15 | -4.56 |
| 2026-07-14 | -4.65 |
| 2026-07-13 | -4.55 |
| 2026-07-10 | -4.97 |
| 2026-07-09 | -5.39 |
| 2026-07-08 | -5.88 |
| 2026-07-07 | -6.09 |